title: Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections.
abstract: Thirty patients with severe bacterial infections were treated with 50 mg of cefodizime per kg of body weight once daily or 50 mg of ceftriaxone per kg once daily for 10 +/- 3 days. The effect of cefodizime and ceftriaxone on the phagocytic capacity and generation of reactive oxygen intermediates after phagocytosis by granulocytes was assessed prior to, during, and after therapy. Flow cytometry was used to study phagocytic capacity by measuring the uptake of fluorescein-labeled bacteria. The generation of reactive oxygen intermediates after phagocytosis was estimated by the quantification of the intracellular conversion of dihydrorhodamine 123 to rhodamine 123. Prior to therapy, patients in both groups exhibited a decreased capacity to phagocytize Escherichia coli and subsequently to generate reactive oxygen intermediates. Granulocyte function increased after the initiation of therapy and normalized within 7 days for the ceftriaxone-treated patients and within 3 days for the cefodizime group (P < 0.05). In the cefodizime group, an enhancement of phagocytic capacity was observed 14 days after the initiation of therapy (P < 0.05). Prior to therapy, phagocytic capacity was significantly correlated with the generation of reactive oxygen products (r = 0.674 and P < 0.005).
authors.affiliation: Department of Infectious Diseases, University Hospital of Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Wenisch
authors.forename: B
authors.initials: B
authors.lastname: Parschalk
authors.forename: M
authors.initials: M
authors.lastname: Hasenhündl
authors.forename: E
authors.initials: E
authors.lastname: Wiesinger
authors.forename: W
authors.initials: W
authors.lastname: Graninger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000097:blood* / Q000188:drug therapy / Q000382:microbiology; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000009:adverse effects* / Q000627:therapeutic use; D004926:Escherichia coli; D005260:Female; D005434:Flow Cytometry; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects; D010586:Phagocytes / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D010587:Phagocytosis / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D017382:Reactive Oxygen Species; D002443:Ceftriaxone; D002439:Cefotaxime; C033356:cefodizime